In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug ...

Novo Nordisk's FY 2025 guidance cuts are driven by softer U.S. Wegovy/Ozempic and GLP-1 trends. Click here to find out why I ...

Novo Nordisk A/S is suffering from headwinds in its core anti-obesity medications market. Click here to find out why NVO ...

Novo Nordisk's legal actions against U.S. pharmacies over compounded copies of its drug Wegovy exclude Hims & Hers, a ...

Novo Nordisk has a commercial relationship with Economist Impact, a division of The Economist Group. The Economist operates ...

Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could ...

Novo Nordisk said second-quarter sales of its blockbuster Wegovy weight-loss drug soared 67% on year, despite waves of U.S.

Sales of Novo Nordisk's blockbuster Wegovy obesity drug rose 67% in the second quarter despite continued competition from ...

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...

The investment conglomerate reported a higher-than-expected profit, aided by a recovery in its te ...

The pharmaceutical company's quarterly sales of its blockbuster Wegovy drug surged by two-thirds, despite many Americans ...

Novo Nordisk's U.S.-listed shares shed a third of their value last week after the company cut its full-year outlook and named ...